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ABSTRACT
Background: Chronic obstructive pulmonary disease (COPD) is the fourth most frequent disease globally,
and its worldwide prevalence is projected to increase in the following decades. Health-related quality of life
(HRQOL) of COPD patients depends on multiple factors. Objective: The aim of this study was to identify
the most important risk factors affecting HRQOL of COPD patients and to measure how specific clinical
parameters can predict HRQOL. Methods: A questionnaire-based cross-sectional study combined with
clinical data was conducted among patients diagnosed with COPD (n 5 321, 52.6% females, mean age 66.4
± 9.5) at the National Koranyi Institute for Pulmonology, Budapest in 2019–2020. The inclusion criteria
were age ≥40 years and existing COPD. Multivariate linear regression analyses were conducted on three
components of the COPD-specific Saint George’s Respiratory Questionnaire (SGRQ-C) and on the physical
(PCS) and mental component scales (MCS) of the 36-Item Short Form Health Survey (SF-36). Multiple
linear regression analysis was performed to evaluate the effects of patient and disease characteristics on
COPD Assessment Test (CAT) scores. Results: We found that frequent exacerbations, multiple comor-
bidities and tobacco smoking were associated with worse HRQOL. Engaging in more frequent physical
activity and better 6-minute walking distance results were associated with better HRQOL. Conclusions: Our
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results indicate that the complex therapy of COPD should focus not only on improving lung functions and
preventing exacerbation, but also on treating comorbidities, encouraging increased physical activity, and
supporting smoking cessation to assure better HRQOL for patients.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory condition of the
lungs characterized by pulmonary symptoms, such as shortness of breath and/or cough, and
extra-pulmonary manifestations, such as cachexia and/or systemic inflammation [1–3]. As of
2016, a total of 251 million people were affected by COPD worldwide, and the disease accounts
for approximately 5% of global deaths yearly [4]. According to projections for future disease
burden, COPD will be the 3rd leading cause of death by 2030 [4], which may be partially linked
to the growing proportion of elderly citizens in aging populations, as the risk of developing
COPD increases with age [5]. The health-related quality of life (HRQOL) of COPD patients
often depends on multiple factors. Thus, patients are usually affected by more than one co-
morbidity, such as cardiovascular diseases, diabetes, and osteoporosis [6]. Furthermore, the
concurrent presence of certain other risk factors, like tobacco smoking, lower body weight, or
lack of physical activity further worsen their HRQOL [7–9].
HRQOL measures the impact of a disease on the day-to-day functioning of patients [10].
According to recent protocols, the treatment model of COPD patients should focus not only on
the evaluation of symptoms, but also on the improvement of patients’ HRQOL [11]. Better quality
life can be achieved by reducing the frequency of exacerbations, improving lung functions, and
encouraging smoking cessation, body weight control, and regular physical activity [6, 7, 12–14].
Studies indicate that the forced expiratory volume in one second (FEV1) often correlates
poorly with HRQOL, thus it doesn't account for extra-pulmonary manifestations of COPD, such
as depression, anxiety, or the patients’ ability to fulfil their daily duties [15]. As a result, in-
struments measuring HRQOL are often included in the assessment of COPD patients
completing the classical clinical parameters. Thus, several general and disease-specific in-
struments can be used to quantify the HRQOL. For instance, the generic 36-Item Short Form
Health Survey (SF-36) includes questions for eight separate HRQOL components [16]. Among
the COPD-specific questionnaires, one of the most frequently used is the COPD-specific Saint
George Respiratory Questionnaire (SGRQ-C) [17]. This instrument measures not only the
severity of COPD symptoms but also the impact of the disease on the activity and everyday life
of the patients. On the other hand, the COPD Assessment Test (CAT) focuses more on the effect
of symptoms (e.g. cough, sputum, dyspnea, chest tightness) [18]. Even though both general and
disease-specific indices are widely used to assess HRQOL among COPD patients, the SGRQ-C is
more reliable in differentiating among patients concerning changes in COPD disease severity
over time compared to other instruments [19].
The complex management of COPD should focus not only on lung function values, other
functional variables, and exacerbation rates but also on the improvement of the patients’
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HRQOL. In the next decades, COPD is projected to increasingly affect the HRQOL of the global
population. Therefore, the goals of our study were (1) to identify risk factors influencing




A cross-sectional study was performed among COPD patients at an inpatient department of the
Hungarian National Koranyi Institute for Pulmonology, Budapest in 2019–2020. Inclusion
criteria were age ≥40 years and recognized COPD (post-bronchodilator FEV1/FVC<70%).
Exclusion criteria were simultaneous asthma, malignant diseases, and/or autoimmune diseases
in terms of ICD-10 definitions. Participation was voluntary, and before signing the consent
document, all patients were informed verbally and in writing about the study and its purpose.
An appointed coordinator conducted the questionnaire-based interviews and filled out the
questionnaires according to the patients’ answers in a timeframe of 30 minutes. Clinical ex-
amination of patients followed the completion of the questionnaire, generally on the same day.
Altogether 321 patients were approached and all of them agreed to participate in the study. The
study protocol and the study were approved by the Ethical Committee of the National Koranyi
Institute for Pulmonology (25/2017) and the Institutional Review Board of Semmelweis Uni-
versity (TUKEB 44402-2/2018/EKU) in compliance with the Helsinki Declaration.
Measurement
Our questionnaire contained items exploring the patients’ socio-demographic, lifestyle, and
disease-specific characteristics. Specific items included age, gender, COPD exacerbation in the
past year (yes/no), body mass index (BMI), current smoking status (yes/no), frequency of
physical activity (≤1 time a week/≥2 times a week), and number of comorbidities. Exacerbation
was defined as an acute and significant change of the patient’s daily symptoms resulting in
change of therapy. As noted by Guo et al., BMI for COPD is more consistent if BMI is cate-
gorized as ≤21, 21.1–29.99, and ≥30 compared to the traditional categories of <18.49, 18.5–25.0,
and >25.1 [20]. To be able to include BMI in our analysis, we used two separate dummy var-
iables to examine the effect of obesity (BMI≥30 vs. reference BMI≤29.9) and underweight
(BMI≤21 vs. reference BMI≥21.1) as risk factors. Regarding comorbidities, cardiovascular
diseases, diabetes, immunological diseases, osteoporosis, musculoskeletal diseases, psychiatric
diseases, allergies, hypersensitivities, and gastrointestinal diseases were included in the analysis.
Data on comorbidities, lung function values, and BMI were collected from the latest medical
records from the past month. Presence of exacerbation was examined from medical records
dating back one year. All other data were collected with questionnaires.
HRQOL was measured by SGRQ-C, COPD Assessment Test (CAT) and Short Form Health
Survey (SF-36) instruments. The SGRQ-C instrument consists of 40 questions divided into three
separate components. The symptoms component describes the frequency and severity of
symptoms over the past three months, the activity component measures the impact of breath-
lessness on activities, whereas the impact component describes the effect of the disease on social
Physiology International 108 (2021) 2, 261–273 263
functioning and mental health of patients [17]. Scores range from 0 to 100 with higher scores
indicating more severe symptoms/limitations [17]. CAT is a unidimensional tool, consisting of
eight items with six response options for each question [18]. Scores range from 0 (best) to 40
(worst) [18]. Finally, SF-36 contains 36 questions measuring eight separate components related to
quality of life (physical functioning, role limitation–physical, role limitation–emotional, vitality,
mental health, social functioning, pain, and general health) [16]. Results range from 0 (worst) to
100 (best) [16]. We decided to calculate two subscales derived from the SF-36 scale, namely the
physical (PCS) and mental (MCS) component scales to decrease the number of concurrent
comparisons. Therefore, we standardized each of the eight components of SF-36 with a Z-score
transformation. Individual Z-scores were calculated by subtracting the population mean from the
respondents’ score and dividing it by the standard deviation. For both the PCS and MCS scales,
scores were multiplied by weighting coefficients calculated from a USA population and stan-
dardized to a T-score with means set at 50 and standard deviation set at 10 [21].
Patients were assigned to one of the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) stages based on their FEV1 results, as measured after the completion of the ques-
tionnaire according to the following specifications: FEV1≥80% as stage 1, 50–80% as stage 2, 30–
50% as stage 3, and ≤30% as stage 4 [22]. The FEV1, FVC (forced vital capacity), and FEV1/FVC
values were measured by spirometry [23]. Exercise capacity was assessed by the 6-minute
walking distance (6MWD) test [24, 25]. We requested patients to walk up and down a hallway
with predefined turning points for a total of 6 minutes. Results were measured in meters.
Statistical analysis
Socio-demographic characteristics and HRQOL scores by gender were analyzed with Pearson’s
Chi-square test, independent samples t-tests, and Mann-Whitney U-test. Normality was
assessed by Shapiro-Wilk’s normality test. Bivariate correlational analyses were performed for
the three components (symptoms, activity, and impact) and for the total score of SGRQ-C, CAT,
and the PCS and MCS scales of SF-36 by including individual variables in our models one at a
time. This was followed by multivariate linear regression analyses for different components of
the SGRQ-C and SF-36 questionnaires and multiple linear regression analysis for the unidi-
mensional CAT questionnaire by including all variables in each respective model. Multivariate
regression analysis was used for SGRQ-C and SF-36 as both are multidimensional tools and are
comprised of more than one dependent variable, whereas multiple linear regression analysis was
used for CAT as it is a unidimensional instrument with a single dependent variable. Maximum
likelihood estimation with robust standard error was used to calculate regression coefficients.
Results of the correlation matrices of each analysis were presented as well. We evaluated the
effect of gender, age, smoking, physical activity, BMI, exacerbations, comorbidities, FEV1/FVC,
and 6MWD results on HRQOL scores in our linear regression analyses. For each model, R2
values were calculated to describe the proportion of explained variance. Significance was set at
P < 0.05. All analyses were conducted in R statistics (lavaan package).
RESULTS
Table 1 shows the descriptive characteristics of the sample. Compared to males (47.4%), females
(52.6%) had significantly higher BMI, greater number of comorbidities, and lower 6MWD
264 Physiology International 108 (2021) 2, 261–273
results. Regarding HRQOL, females reported poorer HRQOL according to the activity and
impact components, and total scores of SGRQ-C. Furthermore, the mean score of the PCS of SF-
36 was also significantly lower among them than among males, whereas their mean score of
CAT was significantly higher.
In the multivariate analysis of SGRQ-C (Table 2), we found that current smokers had higher
scores on the symptom subscale (b 5 0.11, P < 0.05), more comorbidities correlated with
higher activity scores (b 5 0.13, P < 0.01) and total scores (b 5 0.09, P < 0.05). The occurrence
of exacerbations in the past year was associated with an increased score on the symptoms




Total (n 5 321) Male (n 5 152) Female (n 5 169) P-value
Age (years), mean (SD) 66.4 (9.5) 65.8 (9.4) 67.0 (9.7) 0.363
BMI (kg/m2), mean (SD) 26.0 (7.0) 24.7 (6.3) 27.2 (7.4) 0.003
BMI, n (%) 0.036
≤21 82 (26) 47 (31) 35 (21)
21.1–29.99 140 (45) 69 (46) 71 (44)
≥30 92 (29) 35 (23) 57 (35)
Physical activity ≥2 times/week, n (%) 65 (20) 34 (22) 31 (18) 0.405
Current smoker, n (%) 137 (44) 70 (47) 67 (41) 0.306
Exacerbation in the past year, n (%) 165 (51) 82 (54) 83 (49) 0.434
Comorbidities (n), mean (SD) 2.14 (1.7) 1.91 (1.7) 2.35 (1.7) 0.009
GOLD stages, n (%) 0.200
Stage 1 26 (9) 8 (6) 18 (12)
Stage 2 98 (34) 49 (36) 49 (31)
Stage 3 120 (41) 52 (39) 68 (43)
Stage 4 48 (16) 26 (19) 22 (14)
FEV1/FVC (%), mean (SD) 53.4 (13.1) 51.7 (12.7) 55.0 (13.4) 0.054
6MWD (m), mean (SD) 265 (133) 307 (136) 226 (118) <0.001
SGRQ-C, mean (SD)
Symptom 67.1 (20.2) 66.3 (21.4) 67.7 (19.1) 0.747
Activity 65.9 (24.2) 60.8 (25.3) 70.6 (22.2) <0.001
Impact 53.9 (24.9) 48.2 (26.5) 59.0 (22.2) <0.001
Total 59.9 (21.4) 55.3 (23.0) 64.1 (18.9) <0.001
CAT, mean (SD) 24.8 (8.8) 23.8 (8.7) 25.7 (8.7) 0.036
SF-36, mean (SD)
PCS 33.1 (8.5) 35.0 (8.3) 31.4 (8.2) <0.001
MCS 42.8 (11.3) 43.3 (11.4) 42.2 (11.1) 0.395
Note: Pearson Chi-Square test or independent samples t test or Mann-Whitney test P-values were used to
examine the differences between males and females.
BMI: body mass index; CAT: COPD Assessment Test; COPD: chronic obstructive pulmonary disease;
FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; GOLD: Global Initiative for
Chronic Obstructive Lung Disease; MCS: mental component scale; 6MWD: 6-minute walking distance;
PCS: physical component scale; SD: standard deviation; SF-36: 36-Item Short Form Survey; SGRQ-C:
COPD-specific Saint George Respiratory Questionnaire.
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Table 2. Predictors of the COPD-specific Saint George Respiratory Questionnaire's (SGRQ-C) three domains and total score (n 5 280)
Bivariate correlations Multivariate regression analysis
Symptoms Activity Impact Total Symptoms Activity Impact Total
r r r r b b b b
Gender 0.05 0.21*** 0.20*** 0.20*** 0.00 0.06 0.09 0.07
Age 0.02 0.19** 0.06 0.10 0.03 0.04 0.05 0.02
Smoking 0.14* 0.02 0.07 0.06 0.11* 0.02 0.04 0.04
Physical activity 0.16** 0.34*** 0.29*** 0.32*** 0.11* 0.28*** 0.24*** 0.26***
Underweight 0.14* 0.06 0.09 0.10 0.06 0.02 0.04 0.04
Obesity 0.09 0.01 0.01 0.02 0.08 0.03 0.06 0.06
Comorbidities 0.18** 0.23*** 0.15* 0.20*** 0.10 0.13** 0.05 0.09*
Exacerbation 0.42*** 0.33*** 0.37*** 0.41*** 0.35*** 0.20*** 0.28*** 0.29***
FEV1/FVC 0.10 0.16** 0.08 0.12* 0.05 0.01 0.08 0.05
6MWD 0.28*** 0.50*** 0.43*** 0.48*** 0.19** 0.37*** 0.34*** 0.36***
R2 N/A N/A N/A N/A 26.0% 39.7% 34.2% 41.0%
Note: *P < 0.05; **P < 0.01; ***P < 0.001. Multivariate regression. b: standardized regression coefficient; FEV1: forced expiratory volume in the first







(b 5 0.35, P < 0.001), activity (b 5 0.20, P < 0.001), impact (b 5 0.28, P < 0.001) subscales and
total scale (b 5 0.29, P < 0.001). Conversely, more frequent physical activity and better 6MWD
correlated with lower scores on the symptoms (b 5 0.11, P < 0.05 and b 5 0.19, P < 0.01,
respectively), activity (b 5 0.28, P < 001 and b 5 0.37, P < 0.001, respectively), impact















Note: *P < 0.05; **P < 0.01; ***P < 0.001. #: Multiple regression analysis. b: standardized regression
coefficient; FEV1: forced expiratory volume in the first second, FVC: forced vital capacity, 6MWD: 6-
minute walking distance; R2: proportion of explained variance; r: Pearson's correlation.





PCS MCS PCS MCS
r r b b
Gender 0.20** 0.03 0.12 0.04
Age 0.14* 0.07 0.04 0.10
Smoking 0.06 0.15* 0.06 0.09
Physical activity 0.19** 0.16** 0.12* 0.13*
Underweight 0.06 0.11 0.05 0.08
Obesity 0.05 0.00 0.03 0.01
Comorbidities 0.09 0.13* 0.01 0.09
Exacerbation 0.28*** 0.23*** 0.21*** 0.16*
FEV1/FVC 0.13* 0.03 0.03 0.08
6MWD 0.38*** 0.22*** 0.26*** 0.20**
R2 N/A N/A 22.1% 13.7%
Note: *P < 0.05; **P < 0.01; ***P < 0.001. Multivariate regression. b: standardized regression; FEV1: forced
expiratory volume in the first second, FVC: forced vital capacity; MCS: mental component scale; 6MWD: 6-
minute walking distance; PCS: physical component scale; R2: proportion of explained variance; r: Pearson's
correlation.
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(b 5 0.24, P < 0.001 and b 5 0.34, P < 0.001, respectively) subscales and total scale
(b 5 0.26, P < 0.001 and b 5 0.36, P < 0.001, respectively).
Analysis of CAT indicated that increased frequency of physical activity (b5 0.14, P < 0.05)
and better results on the 6MWD test (b 5 0.21, P < 0.01) were inversely associated with CAT
scores, whereas comorbidities (b 5 0.16, P < 0.05) and exacerbations (b 5 0.23, P < 0.001) were
in direct association with CAT scores (Table 3).
In the analysis of PCS and MCS of SF-36 (see Table 4), we found that higher frequency of
physical activity (b 5 0.12, P < 0.05 and b 5 0.13, P < 0.05, respectively) and better results on
the 6MWD test (b 5 0.26, P < 0.001 vs. b 5 0.20, P < 0.01, respectively) were positively
correlated with both scores. However, manifest exacerbations in the past year resulted lower
scores on PCS (b 5 0.21, P < 0.001) and MCS (b 5 0.16, P < 0.05).
When we examined the correlations of individual HRQOL indices with each other, they were
significant except that between MCS and PCS. In the correlation matrix, SF-36 (PCS, MCS)
scores were inversely related to both SGRQ-C and CAT questionnaires because of the opposite
scoring methods employed (Table 5).
DISCUSSION
Our study established that the occurrence of COPD exacerbations, simultaneous comorbid-
ities, and smoking were the most important factors negatively affecting the COPD patients’
HRQOL, whereas the frequency of physical activity and better results on the 6MWD test were
positively associated with their HRQOL. The correlation between SGRQ-C, CAT and SF-36
questionnaires was fair, indicating that these questionnaires examine slightly different aspects
of HRQOL.
Our sample revealed poorer results as measured by the SGRQ-C, CAT, and SF-36 in-
struments compared to the results of other studies measuring the HRQOL of COPD patients
[26–28]. According to the OECD, Hungary ranks in the bottom 20% in health and life satis-
faction [29]. Additionally, smoking rates are among the highest in Europe, along with higher
rates of alcohol consumption and overweight/obesity, and somewhat poorer performance in
Table 5. Correlational matrix of quality of life indices (n 5 296)
Index
SGRQ-C SF-36
Symptoms Activity Impact Total CAT MCS PCS
SGRQ-C Symptoms 1.00
SGRQ-C Activity 0.54* 1.00
SGRQ-C Impact 0.63* 0.73* 1.00
SGRQ-C Total 0.73* 0.87* 0.96* 1.00
CAT 0.55* 0.45* 0.49* 0.54* 1.00
SF-36 MCS 0.39* 0.32* 0.43* 0.57* 0.43* 1.00
SF-36 PCS 0.34* 0.55* 0.54* 0.43* 0.29* 0.02 1.00
Note: Pearson's correlation. *P < 0.001.
SGRQ-C: COPD-specific Saint George Respiratory Questionnaire; CAT: COPD Assessment Test; SF-36:
36-Item Short Form Survey; MCS: mental component scale; PCS: physical component scale.
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terms of physical activity [30]. These factors, both individually and overall, may affect HRQOL
while offering a possible explanation for our results and also explaining why mortality of COPD
in Hungary ranks the highest in Europe [31].
In our study, the number of exacerbations and comorbidities were strongly related to worse
HRQOL. Severe manifestations of COPD are often associated with more frequent exacerbations,
which may have a strong impact on the day-to-day functioning of patients [12]. According to
Miravitlles et al., HRQOL decreases substantially just after an exacerbation, but it tends to
improve fairly quickly within days of the event [12]. However, negative effects of exacerbations
on HRQOL seem to accumulate over time, explaining why patients with more exacerbations tend
to have a lower HRQOL compared to stable patients with fewer events. As for comorbidities,
patients with COPD are often aged individuals and are affected by a plethora of other conditions
as well, such as cardiovascular diseases, malnutrition, depression, and anxiety, that may also affect
their activities and functioning [32]. A previous study identified psychiatric disorders and pe-
ripheral artery diseases as the most important comorbidities with negative impact on HRQOL of
COPD patients [33]. Our results highlight that effective tertiary prevention along with treatment
of any comorbid conditions may be essential for the improvement of HRQOL.
Regarding lifestyle factors, we found that HRQOL was significantly affected by physical
activity and smoking. Studies indicate that the improvement of physical fitness during reha-
bilitation leads to improved functional parameters of COPD patients [34–36]. In our study,
physical activity improved all dimensions of HRQOL and also had a positive effect on the
mental health of patients. According to the WHO, 150 minutes of moderate-intensity aerobic
physical activity or at least 75 minutes of vigorous-intensity aerobic physical activity is advised
per week for the maintenance of health between ages 18 and 65 [35, 37]. For patients over 65,
counseling should focus more on the importance of leisure time physical activity, transportation,
household chores, and gardening for the same amount of time as specified above [37]. Regarding
smoking, physicians offering smoking cessation support for COPD patients should emphasize
that quitting will positively impact the severity of symptoms, which in turn will also improve
their overall HRQOL.
In our study the FEV1/FVC index did not correlate with HRQOL, suggesting that it is in-
dependent of lung capacity values to a certain extent. This is corroborated by other studies
which detected only modest association between FEV1 or FEV1/FVC values and changes in
health status and other disease outcomes [15, 38], such as rate of exacerbations [39]. The results
are, however, often inconsistent [6]. Namely, in the bivariate model we found that higher FEV1/
FVC values were associated with improved outcomes on the activity component and total scores
of SGRQ-C, although this association disappeared when we controlled for additional factors.
The 6MWD results were positively associated with all components of HRQOL. Since physical
activity is strongly associated with 6MWD [40], the latter can be used to assess patients’ level of
fitness and also give an insight for physicians in the HRQOL of their patients [41, 42].
One of the strengths of our study is that we measured HRQOL with three different methods,
and we compared them with clinical/diagnostic test outcomes. Having included all variables in
the models, R2 values were relatively high. This indicates that these variables explain the variance
in our study population fairly well, suggesting that exacerbations, physical activity, and number
of comorbidities affect the HRQOL of COPD patients to a greater extent.
Finally, we must also take into consideration certain limitations of our study, for example the
relatively small sample and the single-center involvement. Since we examined hospitalized
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in-patients, our study sample may have contained a higher proportion of patients with more
severe forms of COPD and thus, worse health-related quality of life. The role of selection bias
cannot be ruled out since the participation was voluntary, which explains the better HRQOL
outcomes of the sample. It may also have been useful to evaluate comorbidities with a multi-
dimensional comorbidity index rather than the total number of comorbidities. An additional
limitation was that in the calculation of MCS and PCS scores, weighting coefficients calculated
from the Hungarian general population were not available, therefore we had to rely on co-
efficients calculated from the general USA population. This may have led to biased results for
SF-36 even though certain studies suggest that this is a viable option when lacking population-
specific estimates, as it produces similar results [43].
COPD is a progressive, multi-organ disease that requires a more complex treatment
strategy due to its diverse effects on the body and the health-related quality of life of the
patients. In this study, the most important factors negatively affecting HRQOL were
frequent exacerbations, number of comorbidities, the lack of physical activity, and current
smoking. Regarding clinical parameters, we found a consistent positive effect between
6MWD and all components of HRQOL. The treatment model of patients should focus not
only on lung function improvement and the prevention of exacerbations but also on the
management of comorbidities, complemented with suggesting physical activity and smoking
cessation.
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